ALT

Altimmune, Inc.

6.11 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Altimmune, Inc. stock is down -31.35% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 18 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
24 May 18:06 17 Jan, 2025 40.00 PUT 10 5
24 May 19:41 24 May, 2024 6.00 CALL 200 718
29 May 16:00 20 Sep, 2024 8.00 CALL 500 375
31 May 18:39 07 Jun, 2024 7.00 CALL 448 1009
03 Jun 13:38 21 Jun, 2024 6.00 CALL 195 634
07 Jun 14:48 17 Jan, 2025 15.00 PUT 29 38
12 Jun 19:07 21 Jun, 2024 6.00 CALL 500 1205
13 Jun 13:30 16 Jan, 2026 10.00 PUT 50 45
13 Jun 13:30 16 Jan, 2026 10.00 PUT 44 45
13 Jun 13:30 16 Jan, 2026 10.00 PUT 50 45

About Altimmune, Inc.

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.